BRAF and metastatic melanoma: In a Phase II randomized clinical trial (KEYNOTE-002) administration of pembrolizumab, a humanized IgG4 anti-PD-1, at two different doses, was compared to investigator’s choice chemotherapy in metastatic melanoma patients who experienced disease progression after treatment with ipilimumab and/or BRAF inhibitor and/or MEK inhibitor.